On Monday, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) opened lower -4.34% from the last session, before settling in for the closing price of $7.60. Price fluctuations for BCRX have ranged from $4.03 to $8.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 190.00% over the past five years. Company’s average yearly earnings per share was noted 68.26% at the time writing. With a float of $196.10 million, this company’s outstanding shares have now reached $205.77 million.
Let’s look at the performance matrix of the company that is accounted for 536 employees. In terms of profitability, gross margin is 97.91%, operating margin of -9.84%, and the pretax margin is -30.09%.
Biocryst Pharmaceuticals Inc (BCRX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Biocryst Pharmaceuticals Inc is 5.32%, while institutional ownership is 82.45%. The most recent insider transaction that took place on Jun 24 ’24, was worth 54,352. In this transaction Director of this company sold 8,600 shares at a rate of $6.32, taking the stock ownership to the 27,831 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 4,689 for $6.00, making the entire transaction worth $28,134. This insider now owns 27,742 shares in total.
Biocryst Pharmaceuticals Inc (BCRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 68.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Check out the current performance indicators for Biocryst Pharmaceuticals Inc (BCRX). In the past quarter, the stock posted a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) saw its 5-day average volume 2.2 million, a negative change from its year-to-date volume of 2.93 million. As of the previous 9 days, the stock’s Stochastic %D was 42.26%. Additionally, its Average True Range was 0.40.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 36.11%, which indicates a significant increase from 26.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.94% in the past 14 days, which was higher than the 52.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.64, while its 200-day Moving Average is $6.59. Nevertheless, the first resistance level for the watch stands at $7.56 in the near term. At $7.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.01. If the price goes on to break the first support level at $7.11, it is likely to go to the next support level at $6.95. The third support level lies at $6.66 if the price breaches the second support level.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
There are currently 207,133K shares outstanding in the company with a market cap of 1.53 billion. Presently, the company’s annual sales total 331,410 K according to its annual income of -226,540 K. Last quarter, the company’s sales amounted to 117,090 K and its income totaled -14,030 K.
